Zorifertinib is under clinical development by Alpha Biopharma and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Zorifertinib’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 29 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Zorifertinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Zorifertinib (AZD-3759) is under development for the treatment of non small cell lung cancer (NSCLC) in patients with brain metastasis. It is a small molecule administered orally. The drug candidate targets epidermal growth factor receptor (EGFR).
Alpha Biopharma overview
Alpha Biopharma is a biopharmaceutical company that develops therapeutics to treat cancer. The company investigating its lead product candidate Zorifertinib, a small molecule tyrosine kinase inhibitor to treat epidermal growth factor receptor mutation positive non-small cell lung cancer accompanied by central nervous system metastasis. Its flagship product ND0612 is currently in late stage development for Parkinson’s disease patients experiencing motor fluctuations. The company works in partnership with AstraZeneca Plc, Tigermed Consulting Co Ltd, Paraxel International Corp and other drug companies to advance its pipeline. The company has offices in Beijing and Shanghai. Alpha Biopharma is headquartered in Chaoyang, Beijing, China.
Quick View Zorifertinib LOA Data
|Highest Development Stage|